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infliximab, ustekinumab) was explored. From the annual eligible psoriasis popula-
tion (N= 16,322), 5% (n= 816), 11% (n= 1,795), and 18% (n= 2,938) were assumed to 
be treated with apremilast for the first, second, and third years. A local expert 
panel provided detailed resource consumption information. Total cost included 
drug acquisition based on drug doses from summaries of product characteristics 
(ex-factory price with mandatory deduction), administration (parenteral drugs), 
and monitoring costs. Unitary costs (€ , 2014) were obtained from national data-
bases. Results: Total budget for the scenario without apremilast was € 193,677,634, 
€ 192,945,426, and € 192,077,291 in the first, second, and third years. Pharmaceutical 
cost represented 95% of the total. Following apremilast introduction, total budgets 
were reduced by € 2,194,450, € 4,827,791, and € 7,900,021 in the first, second, and 
third years. Incremental drug costs/patient comparing the scenario with apremi-
last vs. without apremilast were € −134.44 (−1.13%), € −295.78 (−2.50%), and € −484.00 
(−4.11%) in the first, second, and third years. ConClusions: Apremilast treatment 
for psoriasis patients who have failed to respond to, have a contraindication to, or 
are intolerant of other systemic therapy would imply a budget impact decrease on 
overall healthcare expenditure for NHS. This analysis was limited in that the model 
did not consider cost-effectiveness issues.
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of moderate to severe chronic plaque 
psoriasis for adult patients who have failed to respond to, have a contraindication 
to, or are intolerant to other systemic therapy in Italy. Methods: A budget impact 
model was adapted to the Italian setting using local epidemiological and cost data 
to assess the financial impact of the introduction of apremilast to the market for the 
Italian National Health Service (NHS). The analysis was conducted over a 3-year time 
horizon considering year 2016 as baseline. We used real data of market consumption 
(IMS 2014 data), reflecting the budget holder’s perspective and a real-world 2015 study 
concerning the healthcare resource consumption related to each treatment included 
in the analysis (apremilast, etanercept, infliximab, adalimumab, or ustekinumab). 
Market penetration of apremilast was based on manufacturer’s assumptions. Unit 
costs were taken from Italian standard sources. Frequency of screening and monitor-
ing tests was obtained from real-world data (database analysis). Results: A total of 
≈11,500 patients were considered as the model population at the first year, with an 
assumed 5%-7% annual growth rate. The introduction of apremilast over the next 3 
years, assuming a market share of 1%-5%, 10%-15%, and 15%-20%, for the first, second, 
and third year, respectively, would lead to cost savings varying from a minimum of 
€ 10,150,000 to a maximum of € 15,480,000 for the 3 years. In particular, drug savings 
account for 91% each year, whereas monitoring savings account for 3% and admin-
istration savings account for 6%. ConClusions: This analysis suggests that the use 
of apremilast for the treatment of moderate to severe psoriasis may represent a cost-
saving option for the Italian NHS over the first 3 years of utilisation.
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objeCtives: Routine clinical practice in UK patients with severe dry eye disease 
is a combination of artificial tears (AT) and ocular lubricant ointments. This study 
aims to assess the cost-effectiveness to the UK NHS of the addition of Ikervis® 
(Ciclosporin A; CsA) to routine practice for patients who have not adequately 
responded to therapy. Methods: Using a Markov framework, future health effects 
and costs were modeled. Eligible patients receive six months therapy with Ikervis® 
plus AT and ocular lubricants or AT and ocular lubricants without CsA. Upon com-
pletion, those who respond sufficiently remain on CsA treatment for the dura-
tion of the response, achieving a higher quality of life (HRQoL) and lower AT use. 
Incremental cost effectiveness ratios (ICER) were expressed in GBP (£) per QALY 
gained with costs and health effects discounted at 3.5% over a lifetime time hori-
zon. Deterministic and probabilistic sensitivity analyses were employed to assess 
the effect of uncertainty on the model. Scenario analyses including less stringent 
improvement criteria, alternative approaches to deriving response stratified utility 
values and a shorter initial trial period were performed. Results: Compared with 
AT alone, Ikervis® Resultsin a lifetime cost to the UK NHS of £934 per patient, but 
offers an additional 0.03 QALYs. The ICER is £35,805/QALY gained. At a commonly 
accepted cost-effectiveness threshold of £30,000 per QALY, Ikervis® is cost-effective 
in 32.4% of simulations. Tornado analysis showed the model is most sensitive to 
the incremental benefit on patient’s long-term HRQoL associated with respond-
ing to therapy compared with non-response. ConClusions: The modelling study 
showed that from an NHS perspective, health gains can be achieved at a low cost. 
The Ikervis® ICERs are well below the NICE’s commonly accepted cost-effectiveness 
threshold of £30,000/QALY gained, indicating that Ikervis® in the target patient 
population could represent a cost-effective intervention in the UK.
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objeCtives: This study aimed to assess therapeutic strategies in clinical practice for 
patients with psoriatic arthritis (PsA) or psoriasis and calculate related healthcare 
resources consumption. Methods: An observational retrospective cohort analy-
PSS33
coSt-effectIveneSS analySIS of IntravItreal aflIBercePt In the 
treatment of neovaScular age-related macular degeneratIon In 
greece
Kourlaba G1, Tzanetakos C2, Datseris J3, Rouvas A4, Arzoumanidou D5, Maniadakis N6
1Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 
2National School of Public Health, Athens, Greece, 3Retina Department of Ophthalmology Institute 
of Athens (OMMA), Athens, Greece, 4Attikon University Hospital of Athens, Chaidari, Greece, 
5Bayer Hellas AG, Athens, Greece, 6Department of Health Services Organization, National School 
of Public Health, Athens, Greece
objeCtives: To evaluate the cost-effectiveness of intravitreal aflibercept (IVT-AFL) 
versus intravitreal ranibizumab for the management of neovascular age-related 
macular degeneration (nAMD) in Greece. Methods: A Markov “better-eye-treated” 
model consisting of 6 health states (5 states related to vision impairment, and 
death) was adapted in the Greek healthcare setting to compare monthly (2q4) and 
bimonthly (2q8; following 3 monthly loading doses) treatment with 2 mg IVT-AFL 
with 0.5 mg ranibizumab either on a monthly basis (0.5q4) or as needed (PRN). The 
time horizon of analysis was 20 years. All patients were assumed to discontinue 
treatment at the end of the second year. Clinical inputs and utility values were 
extracted from the literature. The analysis was conducted from a payer perspec-
tive and, as such, only costs reimbursed by the payer were considered (in 2014 
euros). Costs and outcomes were discounted by 3.5% per year. The primary out-
comes were costs, quality-adjusted life years (QALYs), and the incremental cost-
effectiveness ratio per QALY gained. Probabilistic sensitivity analysis (PSA) was 
conducted. Results: IVT-AFL 2q8 was the least expensive regimen (€ 21,930) while 
ranibizumab 0.5q4 was the most expensive (€ 26,203). For all regimens, the total 
cost was driven mainly by the direct nonmedical costs, followed by drug acquisi-
tion costs. In terms of QALYs, IVT-AFL 2q4 was the most efficacious (4.057), while 
IVT-AFL 2q8 was more efficacious (4.049) than ranibizumab PRN (4.025) but less 
efficacious than ranibizumab 0.5q4 (4.052). Although IVT-AFL 2q4 was more effica-
cious than IVT-AFL 2q8, the former cost approximately € 350,000 per QALY gained 
compared with the latter. Both ranibizumab regimens were deemed inferior. PSA 
revealed that at all willingness-to-pay thresholds up to € 335,000, IVT-AFL 2q8 had 
the highest probability of being cost-effective compared with the other treatment 
strategies. ConClusions: Bi-monthly treatment with IVT-AFL may be the most 
cost-effective option for the treatment of nAMD in Greece.
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objeCtives: The objective of this analysis is to evaluate the cost-effectiveness 
of Conbercept versus Ranibizumab in treating neovascular age-related macular 
degeneration (AMD), the third leading cause of irreversible blindness worldwide, 
from China perspective. Methods: A Markov model, based on best corrected visual 
acuity (BCVA) letters, was developed to simulate the progression of neovascular 
AMD among Chinese and to predict the outcomes of Conbercept and Ranibizumab 
treatment over 1 year. The initial distribution of visual acuity was estimated 
from MARINA trial. Disease progression was characterized by a series of annual 
transitions between 5 health states referred to as 90, 75, 60, 45, 30 BCVA letters. 
A patient’s visual acuity was assumed to either increase by 15 letters, remain the 
same, decrease by 15 letters or decrease by 30 letters each year. The transition prob-
abilities of Ranibizumab were estimated based on the reported data of EXTEND II 
trial. The Transition probabilities of Conbercept were extracted from AURORA trial. 
Utility values were taken from a cross-sectional study. Cost data, including drug 
cost, administering cost and caregivers cost in different health states, were derived 
from literatures and direct physician survey. One-way sensitivity analysis was con-
ducted on selected key parameters. Results: One-year total cost was 79,189.94 and 
141,291.23 RMB for Conbercept and Ranibizumab respectively; QALY of Conbercept 
and Ranibizumab was 0.725 and 0.715 respectively. The result suggests a dominant 
ICER of -6,210,129 RMB/QALY, which indicates that Conbercept, when compared with 
Ranibizumab in Chinese AMD population, has demonstrated better efficacy and 
overall lower costs. The one-way sensitivity analysis of key parameters (unit price 
and annual injection times) didn’t change the conclusion, indicating the robust-
ness of the results. ConClusions: Compared with Ranibizumab, Conbercept is a 
cost-effective alternative for the treatment of age-related macular degeneration in 
Chinese people. Conbercept provides better efficacy with overall lower cost.
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of adult patients with moderate to 
severe psoriasis who have failed to respond to, have a contraindication to, or are 
intolerant of other systemic therapy in Spain. Methods: A budget impact model 
was developed to estimate healthcare costs for adults with moderate to severe 
psoriasis over 3 years from the NHS perspective. Target population was defined 
based on epidemiological criteria; psoriasis prevalence (2.30%) and proportion of 
patients on biologic treatment (18%) were applied to national adult population sta-
tistics. Addition of apremilast to the therapeutic arsenal (adalimumab, etanercept, 
